1
|
Sergeant G, Vankelecom H, Gremeaux L and
Topal B: Role of cancer stem cells in pancreatic ductal
adenocarcinoma. Nat Rev Clin Oncol. 6:580–586. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
3
|
Joergensen MT, Brünner N and DeMuckadell
OB: Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the
detection of pancreatic cancer. Anticancer Res. 30:587–592.
2010.PubMed/NCBI
|
4
|
Rosty C and Goggins M: Early detection of
pancreatic carcinoma. Hematol Oncol Clin North Am. 16:37–52. 2002.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Watanabe H, Kawakami H, Yamakawa O,
Satomura Y, Ohta H, Motoo Y, Okai T and Sawabu N: Clinical
usefulness of tumor markers associated with pancreatic cancer.
Rinsho Byori. 42:127–138. 1994.(In Japanese). PubMed/NCBI
|
6
|
Huang C, Wang WM, Gong JP and Yang K:
Oncogenesis and the clinical significance of K-ras in pancreatic
adenocarcinoma. Asian Pac J Cancer Prev. 14:2699–2701. 2013.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Minamoto T: Detection and characterization
of oncogene mutations in preneoplastic and early neoplastic
lesions. Methods Mol Biol. 1105:381–398. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Dabritz J, Preston R, Hänfler J and Oettle
H: Follow-up study of K-ras mutations in the plasma of patients
with pancreatic cancer: Correlation with clinical features and
carbohydrate antigen 19-9. Pancreas. 38:534–541. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Duffy MJ, Sturgeon C, Lamerz R, Haglund C,
Holubec VL, Klapdor R, Nicolini A, Topolcan O and Heinemann V:
Tumor markers in pancreatic cancer: A European Group on Tumor
Markers (EGTM) status report. Ann Oncol. 21:441–447. 2010.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Shin SH, Kim SC, Hong SM, Kim YH, Song KB,
Park KM and Lee YJ: Genetic alterations of K-ras, p53, c-erbB-2,
and DPC4 in pancreatic ductal adenocarcinoma and their correlation
with patient survival. Pancreas. 42:216–222. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Singh N, Gupta S, Pandey RM, Chauhan SS
and Saraya A: High levels of cell-free circulating nucleic acids in
pancreatic cancer are associated with vascular encasement,
metastasis and poor survival. Cancer Invest. 33:78–85. 2015.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Fuccio L, Hassan C, Laterza L, Correale L,
Pagano N, Bocus P, Fabbri C, Maimone A, Cennamo V, Repici A, et al:
The role of K-ras gene mutation analysis in EUS-guided FNA cytology
specimens for the differential diagnosis of pancreatic solid
masses: A meta-analysis of prospective studies. Gastrointest
Endosc. 78:596–608. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Teich N and Mossner J: Molecular analysis
of pancreatic juice: A helpful tool to differentiate benign and
malignant pancreatic tumors? Dig Dis. 22:235–238. 2004. View Article : Google Scholar : PubMed/NCBI
|
14
|
Däbritz J, Preston R, Hänfler J and Oettle
H: Follow-up study of K-ras mutations in the plasma of patients
with pancreatic cancer: Correlation with clinical features and
carbohydrate antigen 19-9. Pancreas. 38:534–541. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Gu J, Wang D, Huang Y, Lu Y and Peng C:
Diagnostic value of combining CA 19-9 and K-ras gene mutation in
pancreatic carcinoma: A meta-analysis. Int J Clin Exp Med.
7:3225–3234. 2014.PubMed/NCBI
|
16
|
Loktionov A, O'Neill IK, Silvester KR,
Cummings JH, Middleton SJ and Miller R: Quantitation of DNA from
exfoliated colonocytes isolated from human stool surface as a novel
noninvasive screening test for colorectal cancer. Clin Cancer Res.
4:337–342. 1998.PubMed/NCBI
|
17
|
Klaassen CH, Jeunink MA, Prinsen CF, Ruers
TJ, Tan AC, Strobbe LJ and Thunnissen FB: Quantification of human
DNA in feces as a diagnostic test for the presence of colorectal
cancer. Clin Chem. 49:1185–1187. 2003. View Article : Google Scholar : PubMed/NCBI
|
18
|
Qi L, Wu L, Zheng S, Wang Y, Fu H and Cui
D: Cell-penetrating magnetic nanoparticles for highly efficient
delivery and intracellular imaging of siRNA. Biomacromolecules.
13:2723–2730. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Qi L and Gao X: Quantum dot-amphipol
nanocomplex for intracellular delivery and real-time imaging of
siRNA. ACS Nano. 2:1403–1410. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yuan H, Zhang L and Zhang Y: Preparation
of high efficiency and low carry-over immobilized enzymatic reactor
with methacrylic acid-silica hybrid monolith as matrix for on-line
protein digestion. J Chromatogr A. 1371:48–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Schnelldorfer T, Ware AL, Sarr MG, Smyrk
TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM and
Farnell MB: Long-term survival after pancreatoduodenectomy for
pancreatic adenocarcinoma: Is cure possible? Ann Surg. 247:456–462.
2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Benassai G, Mastrorilli M, Quarto G,
Cappiello A, Giani U and Mosella G: Survival after
pancreaticoduodenectomy for ductal adenocarcinoma of the head of
the pancreas. Chir Ital. 52:263–270. 2000.PubMed/NCBI
|
24
|
Haug U, Wente MN, Seiler CM, Jesenofsky R
and Brenner H: Stool testing for the early detection of pancreatic
cancer: Rationale and current evidence. Expert Rev Mol Diagn.
8:753–759. 2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Lu X, Xu T, Qian J, Wen X and Wu D:
Detecting K-ras and p53 gene mutation from stool and pancreatic
juice for diagnosis of early pancreatic cancer. Chin Med J (Engl).
115:1632–1636. 2002.PubMed/NCBI
|
26
|
Wilentz RE, Chung CH, Sturm PD, Musler A,
Sohn TA, Offerhaus GJ, Yeo CJ, Hruban RH and Slebos RJ: K-ras
mutations in the duodenal fluid of patients with pancreatic
carcinoma. Cancer. 82:96–103. 1998. View Article : Google Scholar : PubMed/NCBI
|
27
|
Arvanitakis M, Van Laethem JL, Parma J, De
Maertelaer V, Delhaye M and Devière J: Predictive factors for
pancreatic cancer in patients with chronic pancreatitis in
association with K-ras gene mutation. Endoscopy. 36:535–542. 2004.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Pugliese V, Pujic N, Saccomanno S,
Gatteschi B, Pera C, Aste H, Ferrara GB and Nicolò G: Pancreatic
intraductal sampling during ERCP in patients with chronic
pancreatitis and pancreatic cancer: Cytologic studies and k-ras-2
codon 12 molecular analysis in 47 cases. Gastrointest Endosc.
54:595–599. 2001. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ballehaninna UK and Chamberlain RS: Serum
CA 19-9 as a biomarker for pancreatic cancer-A comprehensive
review. Indian J Surg Oncol. 2:88–100. 2011. View Article : Google Scholar : PubMed/NCBI
|